高血压患者的药物坚持促进剂:一种定性研究
Zahra Ghaderi Nasab1, Hamid Sharifi2,3, Parvin Mangolian Shahrbabaki4
1MSc Student, Department of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran.
Frontiers in public health
|December 4, 2024
概括
了解高血压药物坚持是关键. 个人动机,家庭支持和可获得的医疗保健等因素显著改善了患者对高血压药物的坚持,减少了残疾和死亡.
科学领域:
- 公共卫生 公共卫生
- 心脏病学 心脏病学
- 定性研究是一种定性研究.
背景情况:
- 高血压是全球导致残疾和过早死亡的主要原因.
- 高血压的有效管理在很大程度上取决于患者对药物的坚持.
- 确定坚持的促进者对于改善患者的治疗结果至关重要.
研究的目的:
- 探索伊朗东南部高血压患者中促进药物坚持的因素.
- 了解患者对抗高血压药物的坚持的看法.
主要方法:
- 定性传统内容分析.
- 针对25名高血压患者的有目的抽样.
- 实现数据和,以确保全面的洞察力.
主要成果:
- 促进因素分为个人/家庭和组织支持.
- 个人因素包括动机性恐惧,接受疾病,健康的生活方式和监测.
- 家庭支持和组织方面,如负担得起的药物,医疗保健团队的支持,保险和媒体培训至关重要.
结论:
- 多种因素影响高血压患者的药物服药.
- 干预措施应针对个人,家庭和组织支持系统.
- 改善坚持是具有成本效益的,对于降低高血压的负担至关重要.
相关概念视频
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
477
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
477
Antihypertensive Drugs: Direct Renin Inhibitors
490
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
581
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
581


